Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901Z92" target="_blank" >RIV/61988987:17110/18:A1901Z92 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/18:00104336 RIV/65269705:_____/18:00068875 RIV/00843989:_____/18:E0107195
Result on the web
<a href="http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1&SID=F6U7uLFY2vPhQjx4k2S&page=1&doc=1" target="_blank" >http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1&SID=F6U7uLFY2vPhQjx4k2S&page=1&doc=1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000492079" target="_blank" >10.1159/000492079</a>
Alternative languages
Result language
angličtina
Original language name
Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
Original language description
Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacology
ISSN
0031-7012
e-ISSN
1423-0313
Volume of the periodical
102
Issue of the periodical within the volume
3-4
Country of publishing house
CH - SWITZERLAND
Number of pages
7
Pages from-to
206-212
UT code for WoS article
000444753700012
EID of the result in the Scopus database
2-s2.0-85052655336